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Methods: A retrospective monocentric study on 44 clinically suspected amnestic AD or bvFTLD
patients with onset after 65 years and available CSF and clinical data.
Results: The final clinical diagnosis was AD (n5 28; 64%), late-onset bvFTLD (n5 14; 32%), and
others (n 5 2; 4%). Applying the CSF cutoff total-tau/Ab1–42 of 1.06, all the bvFTLD were in the
FTLD range (,1.06, bvFTLD/FTLD), whereas the AD patients were either in the AD (.1.06,
AD/AD) or in the FTLD range (,1.06, AD/FTLD); CSF biomarkers were significantly different
in these three groups, but not neuroradiological features or presence of episodic memory deficit.
Discussion: Late-onset bvFTLD is underdiagnosed. The available CSF biomarker ratio cutoff need
further improvement and overestimated late-onset bvFTLD but could potentially differentiate it from
AD, notably in case of conflicting results.
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The peculiar features of late-onset behavioral variant of
frontotemporal lobar degeneration (bvFTLD), defined by a
disease onset after 65 years, were recently described. Late-
onset bvFTLD accounts for 3%–18% of all bvFTLD, andimer’s Association. This is an open access article under the CC BY-NC-ND
C. Marelli et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 371-379372it is characterized by more frequent memory loss and hippo-
campal sclerosis and less cortical lobar atrophy than clas-
sical presenile-onset bvFTLD [1,2]. The latest bvFTLD
International Consensus Diagnostic Criteria showed low
sensibility for late-onset cases (73% for possible bvFTLD
and 54% for probable bvFTLD), and Alzheimer’s disease
(AD) was the main misdiagnosis; the presence of “cerebro-
spinal fluid (CSF) biomarkers strongly indicative of Alz-
heimer’s disease” is mentioned as exclusion criteria,
without further details [3].
Comparative studies showed lower levels of CSF total-
tau (T-tau) and phospho-tau-181 (P-tau) and higher level
of Ab1–42 in frontotemporal lobar degeneration (FTLD)
compared with AD [4–6]. The highest diagnostic accuracy
in differentiating FTLD versus AD was obtained taking
into account lower T-tau/Ab1–42 [6–8] and P-tau/Ab1–42
[8,9] ratios; some of these studies used autopsy-confirmed
samples [6–8] and suggested cutoff values showed .80%
sensitivity and specificity [6,9]. However, CSF biomarker
analysis was never specifically applied to late-onset bvFTLD
cases.
The aim of this study is to investigate whether CSF clas-
sical biomarkers and ratios could help in detecting late-onset
bvFTLD and in differentiating it from AD.2. Methods
2.1. Study sample
We performed a retrospective study (2007–2014) collect-
ing patients with an initial clinical suspicion of amnestic AD
or bvFTLD with onset after 65 years, from the CSF database
of the Gui de Chauliac University Hospital (N 5 518). All
the patients signed a written informed consent approved by
the local ethics committee (registered DC-2008-417). We
considered only patients with available clinical and CSF
data (n 5 152). To limit possible confounding factors and
alternative diagnosis, patients with psychiatric conditions
able to explain the cognitive and behavioral alterations or
with severe vascular burden (Fazekas score 5 3) [10,11]
were excluded, as well as patients with prominent aphasic
or extrapyramidal presentations; 44 patients were finally
retained.
CSF was collected in polypropylene tubes with standard-
ized conditions [12]. CSF Ab1–42, T-tau, and P-tau were
simultaneously measured in every sample using standard-
ized commercially available Innotest sandwich ELISA
according to manufacturer’s procedures (Fujirebio Ghent
Belgium).
2.2. Study design
The patients were initially classified as AD or late-onset
bvFTLD on clinical basis only, according to the clinical
core of the international criteria [3,13], and blind to CSF
and imaging biomarkers; this classification was performed
by a senior neurologist (CM).We, then, integrated CSF and imaging results, according
to the same international criteria [3,13]. Magnetic resonance
imaging (MRI) were reviewed by a senior neuroradiologist
(N.M.D.C.) for the presence of hippocampal atrophy
(Scheltens score 2) [14], global or focal atrophy, parietal
atrophy (Koedam score) [15], vascular white matter hyperin-
tensities (Fazekas and Schmidt score) [10,11], and presence
of cerebral microbleeds. Functional studies were performed
with technetium-99m (99mTc) perfusion single-photon emis-
sion computed tomography (SPECT) and reviewed by a se-
nior nuclear radiologist (D.D.V.).
Finally, a clinical follow-up (FU) was performed by a se-
nior neurologist (C.M.), to establish a final clinical diagnosis
of AD or late-onset bvFTLD.
At the end of this multistep diagnostic process, we
applied the CSF T-tau/Ab1–42 .1.06 [6] and P-tau/Ab1–42
.0.2 [9] cutoff used for AD diagnosis and investigated
whether these could contribute to the differential diagnosis.
In case of discordance between the two ratios, the T-tau/
Ab1–42 ratio was considered, due to higher specificity [6].
The interest of the Innotest Amyloid Tau Index (IATI)
[16], a modified Ab1–42/T-tau ratio currently used in clinical
practice, was also evaluated.
2.3. Statistical analysis
For samples description, quantitative variables were ex-
pressed as mean and standard deviation and qualitative vari-
ables as percentage. AD versus late-onset bvFTLD
comparisons (Table 1) were performed with the Wilcoxon
test for the quantitative, nonnormally distributed variables
(age, FU duration, and cognitive scores); for qualitative vari-
ables, Fisher tests were used, after checking of the expected
frequencies in each table cell (at least one was ,5).
Samples comparison in the combined classification
(Table 2) was performed with the nonparametric analysis
of variance Kruskall-Wallis test and completed with the
post hoc Nemenyi test to identify the significantly different
group(s). The agreement between the four different diag-
nostic steps was estimated by the kappa coefficient [17].
A kappa value of,0.40 was considered a poor-to-fair agree-
ment; 0.41–0.60, a moderate; 0.61–0.80, an acceptable; and
0.81–1.00, a perfect agreement. Statistical analysis was per-
formed using SAS software, version 9.2 (SAS Institute).
3. Results
We selected 44 patients (F 5 61%) with a mean age at
onset of 70 6 4 years; at the first examination (mean:
3 6 2 years from disease onset), the mean score at the
Mini-Mental State Examination (MMSE) was 20 6 6/30,
and mean score at the Mattis Dementia Rating Scale (Mattis
DRS) was 114 6 18/144.
Cerebral MRI or computed tomography (CT) studies
were available for 36/44 patients (82%): MRI was per-
formed in 29/44 patients and CT in 7/44. A 99mTc SPECT
study was available for 32/44 patients (73%).
Table 1
Clinical, neuroradiological, and biological features of AD and late-onset
bvFTLD patients (after the FU diagnosis according to the international
criteria)
Clinical, radiological,
and biological features
Late-onset
bvFTLD,
n 5 14/44
(32%)
AD, n 5 28/
44 (64%) P value
Sex, F 6 (43%) 20 (71%) .07
Age at onset, y 69 6 3 71 6 5 .23
Age at initial examination, y 72 6 3 74 6 5 .24
Final FU duration, y 5 6 3 4 6 2 .24
MMSE 22 6 5 18 6 5 .02
DRS Mattis 118 6 20 115 6 14 .29
Hippocampal memory deficit 10/14 (71%) 26/28 (93%) .16*
Frontotemporal lobar
atrophy, MRI
3/10 (30%) 0/13 (0%) .07*
Parietal atrophy, MRI 4/8 (50%) 5/13 (38%) .67*
Hippocampal atrophy, MRI 6/9 (67%) 11/14 (79%) .64*
Positive 99mTc SPECT
(according to diagnosis)
10/14 (71%) 12/19 (63%) NA
Biological variables
Ab1–42 700 pg/mL 1/14 (7%) 21/28 (75%) ,.0001
T-tau 400 pg/mL 3/14 (21%) 25/28 (89%) ,.0001*
Ab1–42 700 pg/mL and
T-tau 400 pg/mL
0 19/28 (68%) ,.0001
Abbreviations: AD, Alzheimer’s disease; bvFTLD, behavioral variant of
fronto-temporal lobar degeneration; FU, follow-up; MMSE, Mini-Mental
State Examination; DRS, Dementia Rating Scale; MRI, magnetic resonance
imaging; NA, not available.
Significant P value are in bold.
NOTE. Data expressed as mean 6 standard deviation or number of sub-
jects (%).
*Fisher test.
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core criteria
According to the international clinical core criteria (blind
to radiological and CSF biomarkers), 26/44 (59%) patients
were classified as AD, 11/44 (25%) as possible late-onset
bvFTLD, 4/44 (9%) as both AD and late-onset bvFTLD,
and 3/44 (7%) as neither AD nor late-onset bvFTLD
(Fig. 1, diagnostic step 1). This classification showed a mod-
erate agreement (k 5 0.59 [0.29–0.88]) with the final after
FU diagnosis.3.2. Classification according to core clinical criteria and
to radiological and CSF biomarkers
According to core clinical criteria and to structural (hippo-
campal or focal atrophy),metabolic (99mTcSPECTperfusion
pattern), and CSF biomarkers (Fig. 1, diagnostic step 2), 26/
44 (59%) patients were classified as possible or probable AD
with high, intermediate, or uninformative biomarkers; 4/44
(7%) patientswere classified asADwith frontal presentation;
11/44 (25%) patients were classified as possible or probable
late-onset bvFTLD; and 3/44 (7%) patients remained
“neither AD nor late-onset bvFTLD” (eTable 1). This classi-
fication showed a perfect agreement (k 5 0.88 [0.72–1.00])
with the final after FU diagnosis. Classical CSF biomarkersAb1–42, T-tau, and P-tau allowed to better classify 8/44 pa-
tients (18%): four patients with a clinical diagnosis of late-
onset bvFTLD were diagnosed as AD with frontal presenta-
tion (highCSF biomarkers probability for AD); four doubtful
patients satisfying both AD and bvFTLD clinical criteria
were diagnosed as bvFTLD (CSF biomarkers excluding an
AD biological processes; Fig. 1, diagnostic step 2).3.3. Final classification according to international
criteria and after a clinical FU
After the FU (mean: 5 6 3 years from disease onset;
Fig. 1, diagnostic step 3), AD was diagnosed in 28/44 pa-
tients (64%), late-onset bvFTLD in 14/44 (32%), and corti-
cobasal syndrome (CBS) in 1/44 (2%); in one patient, the
diagnosis still remained undetermined (2%). In details, the
diagnosis of AD was confirmed in 23/26 initial (diagnostic
step 2) AD patients, although in three some atypical features
were retained such as psychiatric problems (2/3), disinhibi-
tion (1/3), epilepsy (1/3), severe executive problems with
perseverations (1/3), hallucinations (1/3), and hyperphagia
(1/3); 2/26 AD were finally diagnosed as bvFTLD and in
1/26 AD patients, the final diagnosis remained undeter-
mined; the four AD patients with frontal presentation were
confirmed as well as the 11 initial (diagnostic step 2) late-
onset bvFTLD patients. Of the three patients “neither AD
nor late-onset bv-FTLD,” one was finally diagnosed as
AD, one as CBS, and one as late-onset bvFTLD. The com-
parison of clinical, radiological, and CSF biomarkers fea-
tures between AD (n 5 28) and late-onset bvFTLD
(N 5 14) according to the final after FU diagnosis
(Table 1) showed no significant differences in age at onset,
age at initial examination, mean FU duration, and presence
of hippocampal memory deficit. The mean MMSE, but not
the Mattis DRS score, was significantly lower in AD pa-
tients. Considering radiological data, no difference was
found between the two groups about hippocampal or parietal
atrophy; frontotemporal atrophy was nonsignificantly more
frequent in the bvFTLD group (P 5 .07). As expected, the
percentage of patients with altered CSF biomarkers was sig-
nificant different in the two groups (Table 1), as well as the
mean CSF biomarker values (data not shown).3.4. Classification according to CSF T-tau to Ab1–42 cutoff
Considering the CSF T-tau/Ab1–42 (AD range: .1.06;
FTLD range: ,1.06) and P-tau/Ab1–42 (AD range: .0.2;
FTLD range: ,0.2) ratios (Fig. 1, diagnostic step 4), 29/44
(66%) patients had the two values in the FTLD range and
15/44 (34%) in the AD range; in only 3/44 patients, the
two ratios were discordant with the T-tau/Ab1–42 in the
AD range and the P-tau/Ab1–42 in the FTLD range. This
classification showed a only moderate agreement
(k 5 0.43 [0.22–0.65]) with the final after FU diagnosis
with a probable overestimation of the number of late-onset
bvFTLD patients. The 29/44 patients with the T-tau/Ab1–42
Table 2
Clinical and biomarkers features of the patients classified in three groups combining the final diagnosis (AD or late-onset bvFTLD) and the CSF T-tau/Ab1–42
ratio (AD or FTLD range)
After FU diagnosis
CSF results in the FTLD range
(T-tau/Ab1–42 ,1.06)
CSF results in the AD range
(T-tau/Ab1–42 .1.06)
P value
bvFTLD,
n 5 14/44 (32%) AD, n 5 13/44 (30%) AD, n 5 15/44 (34%)
Sex, F, (%) 6/14 (43%) 8/13 (69%) 11/15 (73%) .21*
Age at onset, y 69 6 3 73 6 6 70 6 4 .22
Age at initial examination, y 72 6 3 75 6 6 73 6 4 .43
Mean FU duration, y 5 6 3 4 6 2 4.4 6 3 .49
MMSE 22 6 5 18 6 6 18 6 5 .05
DRS Mattis 118 6 20 114 6 14 116 6 15 .53
Hippocampal memory deficit 10/14 (71%) 13/13 (100%) 13/15 (87%) .12*
Fronto-temporal lobar atrophy, MRI 3/10 (30%) 0/6 (0%) 0/7 (0%) .16*
Parietal atrophy, MRI 4/8 (50%) 2/6 (33%) 3/7 (43%) .87*
Hippocampal atrophy, MRI 6/9 (67%) 4/6 (67%) 7/8 (88%) .59*
Positive 99mTc SPECT (according to AD) 0 5/7 (71%) 7/12 (58%) ,.001*
Positive 99mTc SPECT (according to bvFTLD) 10/14 (71%) 1/7 (14%) 0/12 ,.001*
Biological variables
Ab1–42 700 pg/mL 1/14 (7%) 7/13 (54%) 14/15 (93%) ,.0001
T-tau 400 pg/mL 3/14 (21%) 10/13 (77%) 15/15 (100%) ,.0001*
Ab1–42 700 pg/mL and T-tau 400 pg/mL 0 5/13 (38%) 14/15 (93%) ,.0001
P-tau 60 pg/mL 1/14 (7%) 11/13 (85%) 14/15 (93%) ,.0001*
Ab1–42 700 pg/mL and T-tau 400 pg/mL
and P-tau 60 pg/mL
0 5/13 (38%) 13/15 (87%) ,.0001*
Ab1–42 .700 pg/mL and T-tau ,400 pg/mL
and P-tau ,60 pg/mL (normal values)
10/14 (71%) 0 0 ,.0001*
T-tau/Ab1–42 .1.06 0 0 15/15 (100%) ,.0001*
P-tau/Ab1–42 .0.2 0 0 12/15 (80%) ,.0001*
IATI ,0.8 0 6/13 (46%) 15/15 (100%) ,.0001*
IATI 0.8–12 2/14 (14%) 5/13 (38%) 0
IATI .1.2 12/14 (86%) 2/13 (15%) 0
Abbreviations: AD, Alzheimer’s disease; bvFTLD, behavioral variant of frontotemporal lobar degeneration; CSF, cerebrospinal fluid; T-tau, total-tau; FTLD,
fronto-temporal lobar degeneration; FU, follow-up; MMSE, Mini-Mental State Examination; DRS, Dementia Rating Scale; SPECT, single-photon emission
computed tomography; MRI, magnetic resonance imaging.
Significant P values are in bold.
NOTE. Data expressed as mean 6 standard deviation or number of subjects (%).
*Fisher test.
C. Marelli et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 371-379374value in the FTLD range included 14 late-onset bvFTLD, 1
CBS, 1 undetermined case, and 13 AD (after FU diagnosis);
the 15/44 patients with T-tau/Ab1–42 in the AD range
included 15 AD (after FU diagnosis; Fig. 1, diagnostic
step 3 and 4). Of note, two patients considered as AD and
one considered as “neither AD nor late-onset bvFTLD” at
the very initial clinical evaluation (diagnostic step 1) had
CSF ratio in the FTLD range and were confirmed as late-
onset bvFTLD at the FU (Fig. 1, diagnostic step 1, 3, and
4); therefore, the use of the classical and combined CSF bio-
markers allowed a better classification in three more pa-
tients, with a global diagnostic improvement in 11/44
patients (25%).3.5. Combined classification according to the final after
FU diagnosis and T-tau to Ab1–42 cutoff
The classification of the 44 patients combining data from
the final after FU diagnosis and the T-tau/Ab1–42 ratio (AD
range:.1.06, FTLD range:,1.06; Table 2) allowed to sepa-rate the patients in three groups: the “clinical late-onset
bvFTLD/FTLD range” group, indicating the clinically
diagnosed late-onset bvFTLD with CSF ratio in the FTLD
range (n 5 14/14); the “clinical AD/FTLD range” group,
indicating the clinically diagnosed AD with CSF ratio in
the FTLD range (n 5 13/28); and the “clinical AD/AD
range” group, indicating the clinically diagnosed AD with
CSF ratio in the AD range (n 5 15/28). These three groups
did not show clinical or radiological differences. However,
the three groups had a different percentage of patients with
altered CSF biomarkers and the intermediate “clinical AD/
FTLD range” most often had equivocal CSF alteration,
with only 38% of the patients showing alteration in both
Ab1–42 and T-tau (Table 2). The analysis of the IATI results
(Table 2) showed that the currently used cutoff of 1 would
not be able to correctly differentiate AD versus bvFTLD pa-
tients. A more strict IATI values,0.8 were strongly, but not
invariably, in favor of an AD diagnosis, whereas in this
context an IATI value .1.2 was in favor of bvFTLD diag-
nosis. We can, therefore, conclude that the intermediate
AD
Not AD and not bvFTLD
AD and bvFTLD
bvFTLD
Frontal AD
CBS or Undetermined
Diagnosis according to Cut-off
Diagnosis after follow-up
Diagnosis after clinical examination
and biomarker evaluation
Diagnosis after clinical examination
.
4
3
2
1
4
3
2
1
Diagnosis step: 
Diagnosis : 
Fig. 1. Multistep diagnostic process for each subject. Multistep diagnostic process, according to the different clinical, radiological, and biological parameters:
each subject is represented as a part of the pie chart. The details of numbers of subjects and percentages for each diagnostic step are presented in the text. Ab-
breviations: AD, Alzheimer’s disease; bvFTLD, behavioral variant of frontotemporal lobar degeneration; CBS, corticobasal syndrome.
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Importantly, mean CSF biomarkers and ratios values were
very significantly different in the three groups “clinical
late-onset bvFTLD/FTLD range,” “clinical AD/FTLD
range,” and “clinical AD/AD range” (Fig. 2), suggesting
the possibility of further adjusting the cutoff to better sepa-
rate and diagnose patients in the intermediate “clinical
AD/FTLD range” group.
Of note, this three-group classification had also an impor-
tant clinical correspondence as the patients in the intermedi-
ate “clinical AD/FTLD range” group had considerably more
behavioral/cognitive clinical features of bvFTLD, definedFig. 2. Mean biomarkers values in the three groups of patients obtained on the basis
SD. All the two-by-two comparisons are significant. Abbreviations: T-tau, total-t
frontotemporal lobar degeneration; FTLD, frontotemporal lobar degeneration; A
Tau Index.
*Ratios (reference value 5 vertical axis on the right).according to the international criteria [3], than the group
“clinical AD/AD range”, with the exception of the four
AD patients with frontal presentation (Table 3).
None of the “clinical late-onset bvFTLD/FTLD range” pa-
tients had an alteration of the three biomarkers Ab1–42, T-tau,
and P-tau at the same time, and 10/14 (71%) had the three bio-
markers within normal limit, suggestingminor copathology in
this group; 13/15 (87%) patients of the “clinical AD/AD
range” group had an alteration of the three biomarkers at the
same time; the intermediate “clinical AD/FTLD range” group
had more variable results with 5/13 (38%) patients having the
three CSF biomarkers altered at the same time (Table 2).of T-tau/Ab1–42 ratio and final after FU diagnosis. Data expressed as mean6
au; FU, follow-up; SD, standard deviation; bvFTLD, behavioral variant of
D, Alzheimer’s disease; P-tau, phospho-tau-181; IATI, Innotest Amyloid
Table 3
Behavioral and cognitive symptoms of bvFTLD in the 44 patients, according to the clinical after FU diagnosis and to the T-tau/Ab1–42 CSF ratio
Sex/AAO, y
FU at first
evaluation, y
FU at final
evaluation, y
Hippocampal
memory loss
Perseverative,
stereotyped,
or compulsive
ritualistic
behavior
Apathy
or inertia
Hyperorality
and dietary
changes
Neuropsychological
dysexecutive profile
Loss of
sympathy
or empathy
Behavioral
disinhibition
bvFTLD
clinical
features N/6
(initial FU)
bvFTLD
clinical
features N/6
(final FU)
Clinical bvFTLD/FTLD T-tau to Ab1–42 range
F/72 1 5 No Yes Yes Yes Yes 4 4
M/68 2 6 Yes Yes Yes Yes Yes 4 4
F/67 10 10 Yes Yes Yes Yes Yes* 3 4
M/69 2 4 Yes Yes Yes Yes Yes 4 4
F/.65 NA .6 No Yes Yes Yes 3 3
F/75 0 0 Yes Yes Yes Yes 3 3
M/65 1 2 No Yes Yes Yes Yes 4 4
M/72 1 9 Yes Yes No Yes Yes 3 3
F/70 6 7 Yes Yes* No Yes* Yes* 0 3
F/69 1 3 No Yes Yes Yes Yes 4 4
M/66 4 9 Yes Yes No Yes Yes* 2 3
M/67 2 2 Yes Yes Yes Yes No 3 3
M/69 5 7 Yes Yes Yes Yes 3 3
M/68 3 4 Yes Yes Yes Yes 3 3
Clinical AD/FTLD T-tau to Ab1–42 range
M/78 1 6 Yes Yes 1 1
F/68 2 2 Yes Yes 1 1
F/.65 NA 1 Yes 0 0
F/70 4 5 Yes Yes Yes 2 2
M/83 6 7 Yes Yes No No No Yes 2 2
F/.65 NA .2 Yes No Yes* 0 1
F/.65 NA NA Yes 0 0
M/77 0 3 Yes No Yes No Yes 2 2
F/69 1 4 Yes Yes 1 1
F/77 2 5 Yes Yes 1 1
M/67 2 4 Yes 0 0
F/67 2 5 Yes 0 0
F/72 3 6 Yes Yes* Yes* 0 2
Clinical AD/AD T-tau to Ab1–42 range
M/67 3 7 Yes 0 0
M/66 1 3 Yes Yes* Yes* No Yes* 0 3
M/72 1 2 Yes No 0 0
F/67 3 4 Yes 0 0
F/76 0 3 Yes 0 0
F/68 8 11 Yes No 0 0
F/76 2 6 Yes 0 0
F/70 3 4 Yes 0 0
F/69 2 5 Yes 0 0
F/.65 NA .1 Yes No 0 0
F/72 2 4 Yes 0 0
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Accurate antemortem FTLD diagnosis is crucial to
the development and implementation of etiology-based ther-
apies. In this article, we addressed the challenging problem
of antemortem identification of late-onset bvFTLD patients
and of the differential diagnosis from AD. As CSF bio-
markers could give some insights about the underlying
disease-causing neuropathologic process, we analyzed the
interest of this analysis directly applied to this specific diag-
nostic problem.
On the basis of clinical, neuroimaging, and CSF bio-
markers data at the initial evaluation and after a mean FU
of 5 6 3 years, we established a final diagnosis of late-
onset bvFTLD in 14/44 patients (32%). Clinical and neuro-
imaging data confirmed that late-onset bvFTLD patients pre-
sent many overlapping features with AD [1,2]. Indeed, the
bvFTLD international criteria are known to be less
sensitive for late-onset cases, which could therefore remain
underdiagnosed.
As expected, CSF biomarkers were significantly different
within the two groups. Of note, CSF classical biomarkers
(Ab1–42, T-tau, and P-tau) allowed to identify AD with fron-
tal presentation and to exclude AD in some late-onset
bvFTLD satisfying both AD and bvFTLD clinical criteria,
improving final diagnosis in 8/44 patients (18%).
Different CSF biomarkers and cutoff for the FTLD versus
AD diagnosis are available in the literature [5–7,9], and the
T-tau/Ab1–42 ratio is the most used. The T-tau/Ab1–42 cutoff
of 1.06 used in our study, obtained through an ELISA assay
and pathologically or genetically validated, showed a
sensitivity of 78.9% and a specificity of 96.6% in
discriminating FTLD versus AD [6]. We also considered
the P-tau/Ab1–42 ratio of 0.2, showing a sensitivity of
91.7% and specificity of 92.6%, although not pathologically
validated [9].
The application of the T-tau/Ab1–42 CSF cutoff to our
population resulted in 29/44 (66%) patients classified in
the FTLD range and 15/44 (34%) in the AD range, showing
a only moderate (k5 0.43 [0.22–0.65]) correlation with the
final after FU diagnosis: All the clinically diagnosed late-
onset bvFTLD patients were in the FTLD range, whereas
the clinically diagnosed AD patients were either in the AD
(n 5 12) or in the FTLD (n 5 13) range. This suggested a
probable overestimation of the number of late-onset
bvFTLD in the group of clinically diagnosed AD. However,
in three patients initially classified as AD (n5 2) or lacking
definite diagnosis (n 5 1), initial CSF ratios already sup-
ported the final after FU diagnosis of late-onset bvFTLD,
further increasing the proportion of patients correctly classi-
fied on the basis of CSF results to 11/44 (25%). The CSF
analysis could therefore still be considered very useful in
differentiating late-onset bvFTLD from AD.
A closer analysis of CSF data clearly showed different
average values of the CSF biomarkers in the three groups cor-
responding to the combined classification of the patients
C. Marelli et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 371-379378according to the final after FU diagnosis and the T-tau/Ab1–42
cutoff. These average values differences were confirmed for
all the biomarkers and ratios tested and for the IATI index,
currently used in clinical practice. The intermediate group
“clinical AD/FTLD range” more often had equivocal CSF
alterations. Importantly, this CSFdistribution had also a clinical
correspondence, in relation to the number of behavioral/
cognitive clinical features of bvFTLD [3]: the patients in the in-
termediate “clinicalAD/FTLD range” groupwere diagnosed as
ADbut had considerablymore bvFTLD features than the group
“clinical AD/AD range”.
Different reasons could explain why the available cutoff
were not able to clearly separate AD from late-onset
bvFTLD in the intermediate clinical AD/FTLD range group.
First, the T-tau/Ab1–42 cutoff was validated in autopsy
proven classical presenile bvFTLD cases but not in late-
onset cases [6]; in addition, the P-tau/Ab1–42 cutoff was
proposed to discriminated between AD and all the heteroge-
neous clinical variant of FTLD (primary progressive apha-
sia, bvFTLD, FTLD with parkinsonism) and is not specific
for bvFTLD [9]. Second, preanalytical and analytical vari-
ables can lead to considerable variation in CSF biomarkers
values determining problems in directly applying fixed cut-
off from one laboratory to another [12,18,19]. The use of a
ratio could also be discussed because of the challenge of
having similar values, and not only the cutoffs, for Ab1–42,
T-tau, and P-tau in the different laboratories [20]; however,
in the context of the specific diagnostic problem of bvFTLD
versus AD, in which biomarker values are expected to be
reciprocally inverses (Ab1–42 lower in AD than in FTLD;
T-tau and P-tau greater in AD than in FTLD), the use of a ra-
tio is justified, as it may on the contrary smooth the vari-
ability intrinsic to each measure. Finally, a probabilistic
approach, using cutoff ranges, could better reflect the diffi-
culties and uncertainties of the antemortem diagnostic pro-
cess in neurodegenerative diseases [21,22].
Anyway, the strength of the statistical difference among
CSF biomarkers values in the three groups suggested that
the actually proposed cutoffs are valuable and useful and
that they could possibly be further improved taking into ac-
count the previously discussed considerations.
Of interest, in the clinical late-onset bvFTLD/FTLD range
group, only 39% of subjects presented at least one altered
CSF biomarker, suggesting in our late-onset cases less mixed
pathology than expected [8]; however, we cannot exclude
mixed pathology in the clinical AD/FTLD range group.
The lack of neuropathologic confirmation is an im-
portant limitation of this work, as in a large autopsy-
confirmed dementia cohort, the use of the clinical
diagnosis rather than neuropathologic diagnosis as the
gold standard for evaluation of biomarker performance re-
sulted in a 10%–20% underestimation of CSF T-tau and
Ab1–42 biomarker accuracy [8]. Moreover, the actually
available biomarkers are mainly used to confirm or
exclude the diagnosis of AD, and we still lack biomarkers
specific for FTLD.Genetic analysis, notably the progranulin plasmatic
dosage and the MAPT and C9ORF72 genes analysis,
is a possible alternative to neuropathology to obtain a
definite bvFTLD diagnosis [3]; however, in the context of
our population of mainly sporadic and late-onset cases, the
diagnostic yield of these analyses is expected to be quite low.
The strength of our work is the careful and accurate
clinical, radiological, and CSF biomarkers evaluation, in
line with the most recent research criteria, applied for
the first time to the specific context of the differential diag-
nosis between AD and late-onset bvFTLD. This study also
shows the complexity of the antemortem diagnostic pro-
cess in neurodegenerative diseases, requiring a multistep
integration of different clinical, radiological, and biolog-
ical information.5. Conclusion
Late-onset bvFTLD is possibly underdiagnosed. We
confirmed that clinical criteria do not sufficiently discrim-
inate between late bvFTLD and AD, notably at initial dis-
ease stages. Moreover, we showed that structural and
metabolic imaging biomarkers might not be very useful
to detect late-onset bvFTLD cases. We showed that CSF
biomarkers and ratios could be valuable in suggesting
this diagnosis and differentiating it from AD, improving
the diagnosis in 25% of cases. They could be particularly
useful in case of atypical clinical features and in case of
conflicting or borderline biomarkers results, although
caution should be taken in interpreting CSF ratios results
independently of the clinical context and of the other avail-
able biomarkers.
However, the actually available cutoff probably overesti-
mates late-onset bvFTLD in our cohort; their accuracy
should be further improved in relation to the population on
study (late-onset disease) and using autopsy-confirmed sam-
ples. Moreover, a progressive standardization of CSF assays
could ideally permit to generalize the obtained results.
The use of a probabilistic approach with ratio cutoff ranges
could also be useful in clinical practice.Acknowledgments
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1. Systematic review: We address the challenging prob-
lem of antemortem diagnosis of late-onset bvFTLD
versus AD (citations presented). CSF biomarkers and
ratios were proposed for AD versus FTLD differen-
tiation (citations discussed) but never specifically
applied to late-onset bvFTLD.
2. Interpretation: We present a multistep diagnostic
process progressively integrating clinical and
biomarker data; final diagnosis is based on Interna-
tional Criteria (McKhann et al. [13]; Rascovsky
et al. [3]) and follow-up (mean 5 6 3 years). Our
analysis comparing and combining clinical diagnosis
and CSF biomarker ratios suggests that late-onset
bvFTLD is underdiagnosed; CSF biomarkers
improve diagnosis in 25% of cases; clinical criteria
and neuroradiological biomarkers are not sufficiently
discriminative; CSF ratios analysis identified an in-
termediate clinical AD/FTLD ratio range group
requiring further exploration.
3. Future direction: The accuracy of CSF ratio cutoff
should be improved in relation to late-onset patients
and autopsy-confirmed samples; we discuss the need
of CSF assays standardization and the usefulness of a
probabilistic approach with ratio cutoff ranges.References
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